MedPath

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

Early Phase 1
Recruiting
Conditions
Naltrexone
Placebo
Interventions
Registration Number
NCT05007561
Lead Sponsor
San Diego State University
Brief Summary

The study is a randomized, placebo-controlled design with the opioid antagonist, oral naltrexone. Following random assignment, participants will take 50mg of naltrexone or placebo once a day for 7 days. On days 1 - 7, participants complete reports of their feelings of social connection and mood in order to assess more naturalistic feelings in response to opportunities for social connection outside of the laboratory setting. Additionally, at the end of each day, they complete a physical symptoms questionnaire. On the 7th day, participants will come to the SDSU MRI scanning facility to complete tasks designed to elicit feelings of social connection in the fMRI scanner. After the scan, feelings in response to the scanner tasks will be collected.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
210
Inclusion Criteria
  • good health
  • English fluency
  • willing to provide contact information for 4-6 close others
  • willing to provide digital photographs of 2 close others
  • own a smartphone
Exclusion Criteria
  • presence of medical devices, implants, or other metal objects in or on the body that cannot be removed
  • tattooed eyeliner
  • a body habitus prohibiting MRI scanning
  • claustrophobia
  • self-reported chronic mental or physical illness
  • current and regular use of prescription medication
  • previous history of having difficulty taking pills
  • current use of opioid analgesics
  • depressive symptoms above a 9 on Patient Health Questionnaire
  • excessive alcohol use
  • positive urine drug test
  • body mass index (BMI) greater than 35
  • pregnancy or plans to become pregnant in next 6 months
  • positive urine pregnancy test

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NaltrexoneNaltrexone Hydrochloride50mg naltrexone HCL once daily for seven days by mouth
placeboPlacebosugar pill once daily for seven days by mouth
Primary Outcome Measures
NameTimeMethod
Daily feelings of social connection via ecological momentary assessmentpost-treatment, change across 7 days

State feelings of social connection outside of the lab

Bold Oxygen-level Dependent (BOLD) Activations in Prespecified ROIsDay 7, approximately 60 mins after taking study drug

In the MRI scanner, participants read sentences written by people they know and people they do not know in a block design. In a second task they view images of people they know, those they do not know, and other emotional images. Brain activity will be measured as BOLD activity in response to stimuli from known (vs. unknown) people using functional magnetic resonance imaging (FMRI). Based on a priori hypotheses, brain activity will be masked to activity in structural regions-of- interest (ROIs) of the ventral striatum (VS), middle-insula (MI), anterior cingulate cortex (ACC) and ventromedial prefrontal cortex (VMPFC).

feelings in response to neuroimaging tasksDay 7, approximately 150 minutes after taking study drug

Feelings of social connection and general positive affect in response to the neuroimaging tasks will be reported on a scale of 1 (not at all) to 7 (very)

Secondary Outcome Measures
NameTimeMethod
physical symptoms via daily diaryend of day on days 1-7

Physical symptoms previously associated with naltrexone will be assessed as well as the subjective experience of the symptoms.

Trial Locations

Locations (1)

San Diego State University

🇺🇸

San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath